Industry Trends

Dealmaking spurt and key upcoming regulatory guidances point the trajectory ahead in clinical research space.

Weighing overall workplace trends in the life sciences with new survey findings and views on job satisfaction.

Most physicians and many specialists have limited understanding of clinical trial data and research findings presented in prescription drug promotional materials for professional audiences.

Peter O'Donnell discusses Brexit challenges and how the life sciences industry is affected.

The European generic drug industry homed in on the opportunity to “help the EU and member states develop effective policies that support access to medicines for patients.”

The EU’s national health organizations are contemplating to abandon their highly-prized autonomy, and forge common positions and buying strategies for accessing expensive new drugs.

The European Union, looking to re-invent itself in the wake of Brexit, is considering withdrawing policy in the field of public health.

With the U.K. poised to begin the process of leaving the European Union soon, many questions remain as to the specifics of pharma regulation and the wide-ranging effects of this departure.

The European Union effort to forge more cooperation among its national and regional HTA bodies is still a work in progress, as the process has produced varying views on the subject.

A Brussels–based European Union conference on social rights set the stage for how access to healthcare should be widened with improved balance between innovation and affordability.

A prediction by QuintilesIMS consultants states that the industry can look forward to a historically large number and quality of new medicines emerging from the research and development pipeline over the next five years.

The European Reference Network on Rare Respiratory Diseases-a grouping of specialists from more than 60 dispersed centers-has won approval of EU funding to maximize clinical trial efficiency in Europe.

With much happening in the clinical trials industry during 2016, Moe Alsumidaie looks back at some of the innovations that took place. He also looks forward to what the industry can bring us in 2017.

The latest official review of European health strategy has been released at the request of the European Commission in an attempt to address Europe’s healthcare challenges. Peter O’Donnell reports that the clinical trials community is likely to be disappointed at the report’s findings.

Key players gathered in Brussels recently gathered to discuss how health technology assessment should be implemented going forward. While cooperation was the main theme, this approach may have proven to complicate rather than alleviate.

European Biopharmaceutical Enterprises (EBE) warns that Europe’s new drug ideas are going to waste due to a lack of innovative support in the sector. The EBE has offered several requests to stimulate investment, but attracting support from member state governments and the European Commission will be no easy task.

The European Medicines Agency is proposing changes to the current guidelines on first-on-human clinical trials to improve risk-based strategies.

The UK's EU departure threatens to damage the foundation of several European-wide drug safety and innovation initiatives, and also leaves recent boasts from officials on things like partnership, networking, and transparency just empty words.

Some in the financial industry have argued that we may be in the midst of another economic recession. The biopharmaceutical industry has shown resiliency during such times and industry trends point to that being the case again.

Valeant is a hedge fund disguised as pharmaceutical company, with the moral at the end of it's story, poor ethics leads to collapse.

Pharmacists have new prominence in a new European system, created jointly with drugmakers and wholesalers and parallel traders, that will provide on-line identity-checks on each individual medicine from factory to pharmacy.

Slightly more than a thousand healthcare research projects were funded by the European Union between 2007 and 2013, at a cost of $6 billion, revealed Carlos Moedas, European Commissioner for Research, Science and Innovation, at the end of January.

Telling signs from U.S., Russia, Latin America and UK indicate that governments are squeezing as much value as possible out of their spending on pills and procedures.

The burst of new technology enterprises and innovative service providers that specialize in clinical research is a sign that the clinical research industry is starting to look into new ways to solving problems culminating from an antiquated system.

This article evaluates the impact of Allergan’s acquisition on Pfizer’s R&D Portfolio and the long term impact the acquisition will have on Pfizer’s revenue and earnings.

Democratic candidate Hillary Clinton is introducing her Prescription Drug Plan which is meant to benefit patients, however, will Hillary’s plan be good for advancing novel therapies, and will it benefit R&D organizations?

The budget increase for NIH brought strong support from the biomedical research community and medical societies across the board.

 Changes in biopharmaceutical R&D strategies and Technological innovations in clinical research are challenging payers on evaluating novel therapeutics and their involvement in the R&D process.  While at the 2015 New York BIO annual convention, I had the opportunity to interview Nathan Tinker, Executive Director at the New York Biotechnology Association about how these changes are impacting payers. 

In yet another demonstration of how far drug pricing concerns are invading the hitherto sacrosanct territory of drug development, a consortium of national advisory bodies on pricing have written to the chief official responsible for European Union drug research.

The ongoing battle over drug reimbursement and pricing has raised questions about whether the pharmaceutical industry can continue to rely on high U.S. revenues to fund biopharmaceutical R&D. Payers and insurers have become more aggressive in demanding clear evidence of value for high-priced medicines and are rejecting old models for coverage and reimbursement.